HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hearing improvement after bevacizumab for neurofibromatosis type 2.

AuthorsJian-Sheng Diao, Wen-Sen Xia, Shu-Zhong Guo
JournalThe New England journal of medicine (N Engl J Med) Vol. 361 Issue 18 Pg. 1810; author reply 1810-1 (Oct 29 2009) ISSN: 1533-4406 [Electronic] United States
PMID19877310 (Publication Type: Comment, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Hearing Loss (drug therapy, etiology)
  • Humans
  • Neurofibromatosis 2 (complications)
  • Neuroma, Acoustic (drug therapy)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: